Caligan Partners LP
Filing Date
Global Rank
#1,397
/ 8,603
▲ 243
· as of Mar 2026
Top Industry
Biotechnology
78.2%
3Y Alpha vs SPY
+51.3%
Period ended 3 months ago
Filed May 15, 2026 · 55d
14 quarters · since Dec 2022
Clone Performance
Jul 2023–Jul 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+405.2%
SPY
+76.0%
Annualised alpha
+50.8%
Max drawdown
−23.1%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
25 positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
20.4%
−3.0 pts
Top 5
56.8%
−13.6 pts
Top 10
76.9%
−13.8 pts
HHI
906
Diversified−367
Portfolio Trend
14 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $1,502,656,995 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
10 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| IVA | Inventiva S.A. | +2,974,906 | 4,974,906 | $27,610,728 | |
| ADMA | Adma Biologics, Inc. | +2,044,003 | 5,056,511 | $45,559,164 | |
| VOR | Vor Biopharma Inc. | +999,999 | 1,925,066 | $34,343,177 | |
| AVTX | Avalo Therapeutics, Inc. | +753,490 | 1,635,023 | $24,410,893 | |
| RVMD | Revolution Medicines, Inc. | +597,808 | 1,881,708 | $182,996,103 | |
| PCVX | Vaxcyte, Inc. | +355,904 | 2,060,719 | $119,748,381 | |
| TYRA | Tyra Biosciences, Inc. | +332,711 | 1,276,968 | $48,907,874 | |
| XENE | Xenon Pharmaceuticals Inc. | +293,662 | 1,393,027 | $81,004,520 | |
| MAZE | Maze Therapeutics, Inc. | +64,771 | 614,962 | $18,356,615 | |
| ABVX | Abivax S.A. | +10,000 | 1,461,924 | $162,785,237 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
8 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| CGON | CG Oncology, Inc. | 900,000 | $60,912,000 | |
| SYRE | Spyre Therapeutics, Inc. | 878,127 | $44,292,725 | |
| LBRX | Lb Pharmaceuticals Inc | 1,438,070 | $35,462,806 | |
| SABS | SAB Biotherapeutics, Inc. | 7,967,207 | $30,514,402 | |
| IRD | Opus Genetics, Inc. | 6,075,028 | $27,641,377 | |
| MBX | MBX Biosciences, Inc. | 848,590 | $25,330,411 | |
| FTH | Faeth Therapeutics, Inc. | 126,002 | $3,971,583 | |
| AURA | Aura Biosciences, Inc. | 229,864 | $1,537,790 | |
| No positions match the current search. | ||||
25 positions ·
$1,502,656,995 total
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| LQDA |
Liquidia Corp
Healthcare
|
Held | 8,118,892 | $306,406,984 | 20.39% | |
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Added | 1,881,708 | $182,996,103 | 12.18% | |
| ABVX |
Abivax S.A.
Healthcare
|
Added | 1,461,924 | $162,785,237 | 10.83% | |
| PCVX |
Vaxcyte, Inc.
Healthcare
|
Added | 2,060,719 | $119,748,381 | 7.97% | |
| XENE |
Xenon Pharmaceuticals Inc.
Healthcare
|
Added | 1,393,027 | $81,004,520 | 5.39% | |
| MLYS |
Mineralys Therapeutics, Inc.
Healthcare
|
Reduced | 2,772,654 | $75,111,196 | 5.00% | |
| EXEL |
Exelixis, Inc.
Healthcare
|
Held | 1,553,262 | $66,619,407 | 4.43% | |
| CGON |
CG Oncology, Inc.
Healthcare
|
NEW | 900,000 | $60,912,000 | 4.05% | |
| TNGX |
Tango Therapeutics, Inc.
Healthcare
|
Reduced | 2,408,798 | $50,392,054 | 3.35% | |
| TYRA |
Tyra Biosciences, Inc.
Healthcare
|
Added | 1,276,968 | $48,907,874 | 3.25% | |
| ADMA |
Adma Biologics, Inc.
Healthcare
|
Added | 5,056,511 | $45,559,164 | 3.03% | |
| SYRE |
Spyre Therapeutics, Inc.
Healthcare
|
NEW | 878,127 | $44,292,725 | 2.95% | |
| LBRX |
Lb Pharmaceuticals Inc
Healthcare
|
NEW | 1,438,070 | $35,462,806 | 2.36% | |
| VOR |
Vor Biopharma Inc.
Healthcare
|
Added | 1,925,066 | $34,343,177 | 2.29% | |
| SABS |
SAB Biotherapeutics, Inc.
Healthcare
|
NEW | 7,967,207 | $30,514,402 | 2.03% | |
| IRD |
Opus Genetics, Inc.
Healthcare
|
NEW | 6,075,028 | $27,641,377 | 1.84% | |
| IVA |
Inventiva S.A.
Healthcare
|
Added | 4,974,906 | $27,610,728 | 1.84% | |
| MBX |
MBX Biosciences, Inc.
Healthcare
|
NEW | 848,590 | $25,330,411 | 1.69% | |
| AVTX |
Avalo Therapeutics, Inc.
Healthcare
|
Added | 1,635,023 | $24,410,893 | 1.62% | |
| ANIK |
Anika Therapeutics, Inc.
Healthcare
|
Held | 1,435,130 | $20,809,385 | 1.38% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
Added | 614,962 | $18,356,615 | 1.22% | |
| VRCA |
Verrica Pharmaceuticals Inc.
Healthcare
|
Held | 923,910 | $4,887,483 | 0.33% | |
| FTH |
Faeth Therapeutics, Inc.
Healthcare
|
NEW | 126,002 | $3,971,583 | 0.26% | |
| AGIO |
Agios Pharmaceuticals, Inc.
Healthcare
|
Held | 90,000 | $3,044,700 | 0.20% | |
| AURA |
Aura Biosciences, Inc.
Healthcare
|
NEW | 229,864 | $1,537,790 | 0.10% |